PEDIATRICS Vol. 60 No. 6 December 1977, pp. 884-892
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greydanus, D. E.
Right arrow Articles by Hofmann, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greydanus, D. E.
Right arrow Articles by Hofmann, A. D.

Chorioretinitis in the Adolescent: Two Case Presentations With Discussion

Donald E. Greydanus M.D.1, Kenneth G. Noble M.D.1, and Adele D. Hofmann M.D.1

1 Departments of Pediatrics and Ophthalmology, New York University School of Medicine, New York

Two cases of chorioretinitis in adolescence demonstrate the characteristic course of events. It is typically caused by Toxoplasma gondii and is usually acquired congenitally. Toxocara infection must be considered in younger children. Other etiologic agents are rarely implicated in children and youth.

Diagnosis of toxoplasmic chorioretinitis is based on a characteristic history of visual disturbance and specific funduscopic appearance, along with confirmatory serological studies. Management is complex, utilizing pyrimethamine (Daraprim), sulfadiazine, and prednisone in combination for several weeks or months. The combined long-term care by the physician generalist and ophthalmologist is essential. Recognition of adolescent developmental issues is important to insure optimal compliance.

The prognosis is guarded, with 5% to 30% recurrence rates noted after treatment. Severe visual impairment may be seen.

Submitted on May 5, 1977
Accepted on September 14, 1977